Form 4: Teva Pharmaceutical Director Amir Elstein Reports Routine Equity Transactions

Teva Pharmaceutical Industries Ltd. Director Amir Elstein disclosed the vesting of previously granted restricted share units and the grant of new restricted share units, aligning his interests with shareholders.

Summary

• Amir Elstein, a Director of Teva Pharmaceutical Industries Ltd. (TEVA), filed a Form 4 disclosing recent equity transactions.
• On June 6, 2025, 9,632 Restricted Share Units (RSUs) granted on June 6, 2024, vested and were converted into Ordinary Shares.
• Following this conversion, Amir Elstein directly beneficially owns 2,103,963 Ordinary Shares.
• On June 5, 2025, Mr. Elstein was granted 14,492 new Restricted Share Units, which are scheduled to vest on June 5, 2026.
• The transactions were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 5

Explanation: The document reports routine insider equity transactions (vesting and new grants) which are neutral in terms of immediate positive or negative impact on the company's operational or financial performance. They represent standard compensation practices.

Positives

• The grant of new Restricted Share Units to Director Amir Elstein indicates continued alignment of management's interests with those of shareholders.
• The vesting of previously granted RSUs represents a standard component of executive compensation, reinforcing long-term commitment.

Future Outlook

The newly granted 14,492 Restricted Share Units are scheduled to vest on June 5, 2026, indicating a future equity inflow for the director.

Industry Context

The reported transactions are routine insider equity compensation events common across publicly traded companies, particularly for directors, designed to align their long-term interests with company performance and shareholder value.

Stakeholder Impact

• Shareholders: The transactions demonstrate continued equity alignment of a key director with the company's long-term performance, which can be viewed positively as it incentivizes value creation.

Next Steps

• The 14,492 Restricted Share Units granted on June 5, 2025, are expected to vest on June 5, 2026.

Key Dates

Keywords

Teva Pharmaceutical Industries, TEVA, SEC Form 4, Insider Transaction, Director Compensation, Restricted Share Units, RSU, Equity Grant, Stock Ownership, Corporate Governance, Rule 10b5-1